Artificial intelligence aiding drug discovery is no longer science fiction. As biotech and biopharmaceutical companies fully embrace the AI era, this technology is demonstrating its profound value in the medical field. Although the biotech sector, due to its high-beta characteristics and the significant uncertainty of drug development pipelines (with high elimination rates during clinical trial stages), leads many investors to underweight it, AI is showing revolutionary potential in addressing the challenges of new drug development.
Traditional drug development processes are time-consuming and labor-intensive. Before more efficient methodologies emerged, the biotech field remained an area where venture capital found it difficult to easily step in. Healthcare and biotechnology, however, may precisely become the proving ground where AI creates disruptive value. While concerns and fears persist across various sectors about AI replacing jobs and impacting the economic system, if it can be used to conquer more difficult and complicated diseases, its potential benefits will ultimately outweigh the risks. With the accelerated arrival of the agentic era, AI drug discovery has become one of the most imaginative application scenarios for this technology.
Biology remains one of the most challenging scientific fields today. However, Google DeepMind, through its AlphaFold project, solved the protein folding problem and won a Nobel Prize, clearing a critical obstacle on the path to AI-driven drug discovery. As AI models continue to iterate and upgrade, customization costs keep decreasing, and deployment barriers for enterprises gradually lower, the tipping point for technological breakthroughs is approaching year by year. In this context, two biotech stocks, Recursion Pharmaceuticals (NASDAQ: RXRX) and Eli Lilly (LLY), are worthy of close attention.
Recursion Pharmaceuticals, focused on AI-driven drug development, carries significant speculative overtones, yet it has attracted the attention and investment of Cathie Wood of Ark Invest and Jensen Huang of NVIDIA (NASDAQ: NVDA). Although the company’s stock price has dropped by 90%, currently giving it a market cap of $1.9 billion, JPMorgan analyst Priyanka Grover upgraded its rating last December, primarily optimistic about its candidate drug REC-4881 for treating familial adenomatous polyposis. Grover pointed out that several candidates in its “AI-powered R&D pipeline” have been validated by clinical results and pharmaceutical partnerships. While the stock’s $11 price target implies a potential near-triple increase, and the analyst’s endorsement is quite compelling, its high-risk nature still requires careful consideration by investors.
Investors seeking more stable options may look at Eli Lilly. This blue-chip pharmaceutical company recently established a $100 million collaboration with NVIDIA to build a joint innovation lab. Empowered by top-tier computing capabilities enabled by NVIDIA’s Vera Rubin chips and the BioNeMo platform, this biopharma giant is accelerating its release of AI potential. With its vast data assets and the technical support from an AI leader, Lilly’s AI strategy is difficult to bet against. Although current market focus is on GLP-1 drugs, AI drug discovery could become the next growth engine, much like how NVIDIA’s gaming business served as a transformative foundation a decade ago. Currently valued at under $1 trillion, Eli Lilly is showing attractive valuation appeal.
